Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy by Zorrilla, Carmen D & Tamayo-Agrait, Vivian
© 2009 Zorrilla and Tamayo-Agrait, publisher and licensee Dove Medical Press Ltd. This is an Open Access article   
which permits unrestricted noncommercial use, provided the original work is properly cited.
HIV/AIDS - Research and Palliative Care 2009:1 41–53
HIV/AIDS - Research and Palliative Care
41
R e V I e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Pharmacologic and nonpharmacologic options 
for the management of HIV infection during 
pregnancy
Carmen D Zorrilla 
Vivian Tamayo-Agrait
Department of Obstetrics and 
Gynecology, University of Puerto Rico 
School of Medicine, Maternal Infant 
Studies Center (CeMI), San Juan, 
Puerto Rico
Correspondence: Carmen Zorrilla 
Professor, Obstetrics and Gynecology, 
University of Puerto Rico School of 
Medicine, Maternal Infant Studies Center, 
San Juan, Puerto Rico, 00936-5067 
Tel +787 771 4739 
Fax +787 771 4739 
email carmen.zorrilla@upr.edu
Abstract: Over the past decade, significant advances have been made in the treatment of HIV-1 
infection using both pharmacologic and nonpharmacologic strategies to prevent mother-to-child 
transmission (MTCT). Optimal prevention of the MTCT of HIV requires antiretroviral drugs 
(ARV) during pregnancy, during labor, and to the infant. ARVs reduce viral replication, lower-
ing maternal plasma viral load and thus the likelihood of MTCT. Postexposure prophylaxis of 
ARV agents in newborns protect against infection following potential exposure to maternal 
HIV during birth. In general, the choice of an ARV for treatment of HIV-infected women 
during pregnancy is complicated by the need to consider the effectiveness of the therapy for 
the maternal disease as well as the teratogenic or teratotoxic potential of these drugs. Clinicians 
managing HIV in pregnancy need to discuss the potential risks and benefits of available therapy 
options so that mothers can make informed decisions in choosing the best treatment regimen 
for themselves and for their children.
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Introduction
According to the World Health Organization (WHO), an estimated 15.7 million 
women and 2.1 million children under the age of 15 years were living with AIDS as 
of December 2008.1 One of the great success stories has been the influence of perinatal 
interventions on the reduction of mother-to-child transmission (MTCT) worldwide. 
This has been more evident in developed countries where interventions are more 
complex and effective but costly.
Without interventions, the risk of such vertical transmission of HIV has been 
estimated to be 15% to 35% worldwide.2 In some developing countries, for example, 
Botswana, Zimbabwe, and Swaziland, the HIV epidemic has reversed the gains in 
infant survival made prior to 1999.3,4 Attempts to eradicate perinatal transmission of 
the disease have led numerous national and international health agencies to institute 
guidelines for the management of the woman and her infant during the antepartum, 
intrapartum, and postpartum periods.
In contrast with general guidelines for the management of adults with HIV infec-
tion, the consensus for the management of pregnant women with HIV infection is that 
antiretroviral (ARV) therapy should be initiated and continued for the duration of the 
pregnancy regardless of viral load and CD4 cell count in order to reduce MTCT;5–7 for 
women who are receiving antiretroviral drugs solely for prevention of perinatal trans-
mission, however, delaying initiation of prophylaxis until after the first trimester can 
be considered.5 In developed countries, the use of highly active antiretroviral therapy HIV/AIDS - Research and Palliative Care 2009:1 42
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(HAART; which includes 2 nucleoside/nucleotide reverse 
transcriptase inhibitors [NRTIs] with a protease inhibitor 
[PI]), ARV prophylaxis for the mother and fetus and then the 
infant, elective cesarean delivery, and infant formula rather 
than breastfeeding have reduced the incidence of MTCT from 
between 15% to 25% to less than 2%.8 In less developed 
areas, simpler and more affordable ARV regimens are being 
offered to treatment-naïve pregnant women and their new-
borns; these involve combinatorial ARV approaches, where 
possible, or single agent treatment, most notably the use of 
the nonnucleoside reverse transcriptase inhibitor (NNRTI) 
nevirapine (NVP), where lack of resources is a limiting 
factor.9 The reductions in the rate of perinatal HIV transmis-
sion have been evident worldwide (including the Caribbean) 
due to the diverse interventions and programs supported by 
a variety of international funding agencies.10,11
Perinatal transmission
One major achievement in the reduction of the MTCT of 
HIV was the Pediatric AIDS Clinical Trials Group Protocol 
076 (PACTG 076)12 regimen involving zidovudine (AZT), 
which in 1994 was shown to reduce the risk of MTCT by 
nearly 70%. The implementation of PACTG 076 coupled 
with increased antenatal HIV counseling and rapid testing 
in the United States and other countries with higher level 
resources13,14 have substantially decreased the perinatal 
MTCT of HIV . In general, although the risk of MTCT is 
related to maternal viral load, studies have shown a continued 
risk of MTCT even at low maternal plasma HIV RNA levels 
(1000 copies/mL);15,16 in addition, the protective effect of 
antenatal ARV therapy increases with its complexity and 
duration and results in a decline in the rate of MTCT to 
around 3%.17–19
Projects to prevent MTCT in resource-limited settings 
have focused primarily on the provision of single-dose intra-
partum and neonatal ARV as alternatives to more complex 
regimens. The first drug to be employed was the NRTI azi-
dothymidine (AZT; zidovudine); subsequently NVP became 
the preferred agent.12,19–21 The most widely adopted regimen 
and that initially recommended by the WHO as an ‘absolute 
minimum,’ is a single dose of NVP given to the mother at 
the onset of labor and then a single dose given to the infant 
72 hours postpartum.9 Owing to the potential for develop-
ment of resistance, however, the WHO has since modified 
this guideline to recommend combination ARV treatment 
as the preferred regimen for the mother where there is the 
capacity to do so.22,23 Thus, while single agent treatments are 
effective in reducing MTCT, the development of affordable 
regimens with superior efficacy and tolerability profiles 
remains an urgent global priority.
Antiretroviral therapy: mechanism 
of action
Since high maternal viral load increases the likelihood of 
MTCT, one of the most effective mechanisms of action is 
simply the reduction of maternal HIV-1 RNA levels, which 
in turn lowers fetal prenatal and postnatal HIV exposure from 
maternal plasma, genital secretions,24 and breast milk.25
Another possible mechanism of protection is pre-exposure 
of the infant to ARV agents that can cross the placenta 
which may protect the infant from exposure to a maternal 
genital tract virus during passage through the birth canal.26 
In addition, postexposure prophylaxis provided through drug 
administration to the infant after birth would protect against 
a cell-free or cell-associated virus that might have entered 
the fetal/infant system during labor through maternal-fetal 
transfusion during uterine contractions or by the infant swal-
lowing genital tract secretions during passage through the 
birth canal.
Antiretroviral therapy in pregnancy
This section reviews the potential toxicity of drugs that may 
cross the placenta, potential adverse effects that may be 
exacerbated during pregnancy, potential short- and long-term 
effects on the fetus and newborn child, and dosing changes 
that may be required owing to natural physiologic changes 
during pregnancy (eg, plasma volume expansion,27 increase 
in the glomerular filtration rate,28 and changes in CYP1A2, 
CYP3A4, and CYP2D6 activity – important enzymes 
involved in the xenobiotic metabolism).29,30
Placental antiretroviral drug transfer
In mammals, the placenta separates the maternal and fetal 
circulation systems while ensuring fetal growth and develop-
ment by transferring oxygen, carbon dioxide, nutrients, and 
waste products. Transplacental transfer occurs via passive 
diffusion, facilitated diffusion, active transport, pinocytosis, 
phagocytosis, and filtration.31 Of these, the most common 
mechanism for drug transfer is passive diffusion. Thus, the 
factors defining Fick’s law of diffusion (eg, membrane thick-
ness, surface area, and the concentration gradient) determine 
the degree of placental drug transfer. The drug properties 
that govern the extent of this transfer include: molecular 
weight, pKa (the pH at which the drug is 50% ionized), 
lipid solubility, and the affinity of the substance to plasma 
proteins.31 In general, compounds with a molecular weight of HIV/AIDS - Research and Palliative Care 2009:1 43
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less than 500 Da exhibit complete transfer across the human 
placenta. Nonionized compounds cross the placenta more 
readily than ionized compounds do and drugs with greater 
lipophilicity (ie, the ability of a compound to dissolve in 
lipids and nonpolar solvents). Since most drugs are weak 
acids or bases, changes in pH affect their ionization and, in 
turn, lipophilicity and membrane permeability.31
Currently, there are eight US Food and Drug Administra-
tion (FDA)-approved NRTIs: abacavir (ABC), didanosine 
(ddl), emtricitabine (FTC), lamivudine (3TC), stavudine 
(d4T), tenofovir (TDF), zalcitabine (ddC), and AZT. All 
have molecular weights of around 250 Da, sufficiently small 
enough to pass through the placenta by simple diffusion. As 
expected, all have been shown to cross the placenta in the 
human, monkey, rabbit, rat, and mouse.32–39 The four FDA-
approved NNRTIs: delavirdine (DLV), efavirenz (EFV), 
etravirine (TMC125) and NVP have molecular weights 
of 553 Da, 316 Da, 316 Da, 435 Da, and 266 Da, respec-
tively.40–43 Transplacental transfer of EFV is strongly sus-
pected in humans since case reports of central nervous system 
malformations in neonates born to women exposed to EFV 
have led the manufacturer to modify the ‘‘pregnancy risk’’ 
warning label on EFV .41,44–46 It has also has been reported to 
cause central nervous system abnormalities in infants born to 
cynomolgus monkeys.50 With a molecular weight of 266 Da, 
transplacental transfer of NVP would be expected and indeed 
has been confirmed in humans.47–49 With a molecular weight 
of 553 Da, limited transplacental diffusion of DLV would be 
expected to occur. Table 151–64 lists the chemical and physical 
properties that govern the diffusion of compounds across 
the placenta of the remaining classes of HIV drugs: PIs, 
fusion inhibitors, entry inhibitors, and an integrase inhibitor. 
In addition, the pKa of these compounds indicates that they 
are weakly basic and thus slightly ionized at physiologic pH, 
thus further limiting transplacental diffusion.51–64
Lipophilicity, which is measured as a partition coefficient 
or a distribution coefficient ratio, is one of the most impor-
tant characteristics governing the transfer of drugs through 
cellular membranes.31 Generally, the cellular permeability 
of a compound is directly proportional to its lipophilicity. 
However, a compound with too high a partition/distribu-
tion coefficient is sequestered in the cell membrane (a lipid 
bilayer), thus reducing its diffusion into the cell. Therefore, 
highly lipophilic drugs have essentially the same problem 
as hydrophilic drugs; they have difficulty diffusing through 
multiple aqueous membrane interfaces necessary to enter the 
fetal circulation. The ideal partition coefficient for membrane 
diffusion from studies of the blood-brain barrier is between 
-0.2 to 1.3 (log P, partition coefficient).62,65 The partition 
coefficients for the protease, fusion, and integrase inhibitors 
listed in Table 1 are all outside this range, indicating that 
these drugs are highly lipophilic and should be trapped within 
Table 1 Chemical and physical properties of HIV protease, fusion, and integrase inhibitors
Molecular 
weight (Da)
Partition/distribution 
coefficients
pKa1 Water solubility, pH 7.4 Pregnancy 
category2
Protease inhibitors
Amprenavir mesylate3 50554 3.30 or 4.2060 NR Low: ∼0.06 g/L60 C
Indinavir sulfate 71255 2.9063 5.5062 Low: 0.07 g/L60 C
Lopinavir 62956 5.0962 Nonionized62 Practically insoluble62 C
Nelfinavir mesylate 66457 4.0060 pKa1 = 6.0061 
pKa2 = 11.1061
Very low61,62 B
Ritonavir 72158 5.2060
3.9962
pKa1 = 1.7662 
pKa2 = 2.5662
Low: 0.005 g/L60 B
Saquinavir mesylate 67159 4.1060 7.00 or 5.5060 Low: 0.004 g/L60 B
Fusion/entry inhibitors
enfuvirtide 449253 -0.87553 4.664 Low53 B
Maraviroc 51452 NR pKa1 = 3.3052
pKa2 = 2.5652
High52 B
Integrase inhibitor
Raltegravir 48351 NR NR High51 C
1pKa, pH at which 50% of the agent is ionized. 2Category B: drugs that, in animal reproduction studies, fail to demonstrate a risk to the fetus; however, well-controlled studies 
of pregnant woman have not been conducted. Category C: drugs where safety in human pregnancy has not been determined; animal studies are either positive for fetal risk or 
have not been conducted. 3Amprenavir mesylate is no longer commercially available and has been replaced with fosamprenavir calcium, a prodrug of amprenavir. 
Abbreviations: HIV, human immunodeficiency virus; NR, not reported.HIV/AIDS - Research and Palliative Care 2009:1 44
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cellular membranes and would be expected to exhibit very 
limited cross-placental transfer.
The placenta also plays an important role in the synthesis 
of hormones, steroids, and peptides and facilitates the 
transfer of nutrients and other physiologic substances via 
specific transporters necessary for a successful pregnancy.66 
The specificity of these transporters is not strictly limited to 
physiologic substrates. Xenobiotics (including environmental 
pollutants, toxins, and therapeutic and nontherapeutic agents) 
that bear structural similarity to physiologic substrates are 
also recognized by placental transporters. Thus, although 
placental transporters can protect the fetus from potential 
adverse effects of xenobiotics, they also play a crucial role 
in the transfer of therapeutic agents across the maternal-fetal 
interface.66,67
The placental transporters that carry the widest 
variety  of  xenobiotics  belong  to  the  adenosine 
triphosphate-binding cassette (ABC) superfamily of active 
membrane transporters.68,69 These include P-glycoprotein 
(P-gp; eg, multidrug resistant [MDR]1, ABC1), breast 
cancer–resistant protein (eg, ABCG2), and several members 
of the multidrug-resistant protein (MRP; eg, ABCC) 
subfamily, such as MRP1, MRP2, and MRP5 (eg, ABCC1, 
ABCC2, and ABCC3).68–71 In the placenta, they prohibit 
the maternal-fetal transfer of potentially toxic compounds.68 
Of these transporters, P-gp extrudes the widest range of 
chemically diverse substrates, hydrophobic or slightly 
charged with average molecular weights of approximately 
800 Da for neutral molecules.72–74 MDR1/P-gp expression 
in the human placenta has been demonstrated at the protein 
level,75 and is located at the apical surface of the syncytio-
trophoblast membrane, where it transports substrate from 
the trophoblast into the maternal plasma and away from the 
fetal circulation.68,76
The substrates of P-gp include anticancer drugs (eg, 
vincristine, vinblastine, the anthracyclines, etoposide, taxol, 
and mithramycin), cytotoxic agents (eg, colchicine and 
emetine), and HIV PIs (eg, nelfinavir [NFV], saquinavir 
[SQV], indinavir, and ritonavir).77,78 Chappuy and colleagues79 
confirmed that P-gp plays a major role in limiting penetration 
of PIs into the fetus. This could be advantageous at early 
stages of embryonic and fetal development since it reduces 
exposure to potentially teratogenic drugs at a time when the 
MTCT of HIV rarely occurs.80
Preloading of the infant before birth with an effective 
anti-HIV drug requires choosing drugs such as AZT that 
cross the placenta readily.5,81,82 Placental P-gp is an important 
factor that limits PI penetration, making PIs unsuitable as 
a prophylactic agent.83,84 Interestingly, according to the 
product package insert,52 the fusion inhibitor maraviroc is 
a substrate for the with an affinity of 35 µM (Ki) and, thus 
is also probably of limited use as a prophylactic to limit the 
MTCT of HIV . Still, these properties could allow MVC to be 
effective in reducing maternal HIV viral load while protecting 
the fetus from exposure to a drug.
Nucleoside/nucleotide reverse 
transcriptase inhibitors
Nucleoside/nucleotide reverse transcriptase inhibitors have 
a small molecular size (∼250 Da), can cross the placenta 
by simple diffusion, and can cause toxic damage to both 
mother and infant.85 The most serious side effects associ-
ated with this class of drugs are anemia and, when used in 
combination therapy, lactic acidosis. However, based on 
pregnancies documented in the Antiretroviral Pregnancy 
Registry (2008),86 the most frequently used nucleoside 
analogs – AZT, 3TC, and d4T – do not increase teratogenicity 
by more than 2-fold compared to controls. Follow-up of more 
than 20,000 children who had received AZT prophylaxis did 
not show any serious adverse effects.87 An analysis of the 
causes of death in 223 children who died, within the first 
5 years of life, ruled out drug-related causes.87 In contrast, 
in a prospective study of 2644 children without infection 
who had been exposed to HAART,88 neurologic symptoms 
with persistent mitochondrial dysfunction were reported in 
0.26% versus 0.01% in the general population. Nonspecific 
changes in cerebral magnetic resonance imaging scans in 
children perinatally exposed to AZT (plus 3TC)89 have 
been interpreted as a sign of neurotoxicity. Twenty-four 
weeks after combined nucleoside exposure, raised lactate 
values as well as impairment of hematopoiesis were noted in 
children.90 Mitochondriopathies have been observed at least 
twice in pregnant women taking a combination of d4T/ddI 
plus NFV or NVP.91 For these reasons, the combination 
d4T/ddI therapy is not recommended for use in pregnancy.5 
Hepatic toxicity with hyperbilirubinemia was described in 
one pregnant woman who died of sudden acute liver failure 
following the administration of AZT/3TC/NFV .92
There is some concern about the effect of administering 
NRTIs, particularly AZT, during pregnancy. Lower levels 
of mitochondrial DNA have been found in the placenta and 
cord blood of HIV-infected women receiving AZT during 
their pregnancy compared to uninfected women.93 In another 
study, infants born to HIV-infected women exposed to AZT 
during their pregnancy had lower levels of mitochondrial 
DNA in their peripheral blood leukocytes at one and two HIV/AIDS - Research and Palliative Care 2009:1 45
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years of age than those born to HIV-infected women who 
were not exposed to AZT; both had lower levels compared 
to infants born to uninfected women.94 Preclinical studies in 
monkeys showed that offspring receiving perinatal (in utero 
and for six weeks after birth) exposure to AZT alone as well 
as double-NRTI combinations (AZT/3TC, AZT/ddI, or 
d4T/3TC) had skeletal muscle mitochondrial DNA deple-
tion and other abnormalities that persisted for 1 year com-
pared to offspring of monkeys not receiving perinatal drug 
exposure.95 The long-term relevance of these findings is not 
known. Nevertheless, AZT is an important component of the 
combination therapies used to reduce MTCT.
In animal experiments, tenofovir was not found to have 
any maternal toxicity but fetal growth was lowered by 13% 
versus controls and was associated with a slight decrease in 
bone density.96 Subsequently, it has been found that long-term 
use in adults may induce renal toxicity and osteomalacia in 
some patients.97 In studies of TDF-containing regimens in 
pediatric patients, loss in bone mineral density was observed98 
but renal toxicity was not reported;99 in a third study, renal 
toxicity was seen in a small number of children100 Studies 
of the use of TDF in regimens to reduce MTCT101,102 have 
suggested that it may be helpful in preventing induction of 
resistance to NVP (reviewed by Foster and colleagues).103 
Currently, the US PHS Perinatal Guidelines recommend use 
of TDF as a component of combination regimens in preg-
nancy in the context of coinfection with hepatitis B virus, but 
otherwise only after consideration of other alternatives.5
Nonnucleoside/nucleotide reverse 
transcriptase inhibitors
Nonnucleoside/nucleotide reverse transcriptase inhibitors 
block reverse transcriptase by binding at a different site on 
the enzyme than NRTIs.104 The molecular sizes are similar 
to those of NRTIs and thus are expected to readily diffuse 
across the placenta. In the prevention of MTCT, NVP has 
been employed successfully, particularly in combination 
with AZT or 3TC.105,106 However, owing to the enhanced 
risk of liver toxicity during the first 18 weeks of treatment 
in women with CD4+ T-cell counts of more than 250/µL, 
patients must be monitored closely, especially during dose 
escalation.5 Treatment with NVP in pregnant women is only 
recommended following very careful assessment of the 
benefit:risk ratio.5 Perinatal single- and 2-dose prophylaxis 
has resulted in the development of drug resistance.107,108 If a 
mother gives birth less than 2 hours following the administra-
tion of NVP or has not received any prior NVP, the newborn 
should receive a dose immediately after birth and another 
dose after 48 to 72 hours.47,109,110 Data indicate that there may 
be clinically significant levels of NVP in plasma for more 
than two weeks after stopping chronic therapy as well as 
after a single dose of NVP.111 Resistance mutations have been 
identified postpartum in women who received single-dose 
intrapartum NVP prophylaxis as well as in women who had 
stopped NVP-containing combination regimens taken dur-
ing pregnancy for the prevention of MTCT.112,113 In the latter 
study,113 NVP resistance was seen in 13% of women despite 
the staggered discontinuance of ARV drugs (in which the 
nucleoside backbone was continued for five days after stop-
ping NVP). Furthermore, in the Perinatal HIV Prevention 
Trial, women who received a single dose of NVP intrapar-
tum were less likely to achieve virologic suppression at six 
months, compared with women not receiving intrapartum 
NVP, suggesting that their responses to subsequent NNRTI 
therapy were compromized; those that had NVP resistance 
mutations had an even poorer response.114 Preliminary data 
from a South African study115 suggest that administration of 
a single dose of NVP combined with AZT/3TC and given 
intrapartum and then for three or seven days postpartum, 
may reduce the development of resistance compared with 
the administration of single-dose NVP.
To our knowledge, there are no published studies 
reporting on the use (either pharmacokinetics or efficacy) 
of etravirine (TMC125), a recently approved drug, during 
pregnancy. Efavirenz has been reported to cause embryonic 
toxicity in rhesus monkeys and neural tube defects in humans 
after first trimester exposure.45,86,116 Thus, EFV is not used 
during the first trimester and is used only after the second 
trimester when there is no alternative treatment option and 
provided that reliable contraception is then practiced after 
delivery.5
Protease inhibitors
Protease inhibitors prevent HIV replication by inhibiting the 
activity of HIV-1 protease, an enzyme used by the viruses to 
cleave nascent proteins for final assembly of new virions.117 
The transplacental diffusion of agents of this class is partly limi   
ted by their molecular weight (Table 1) but most importantly 
by their affinity for the placental P-gp transporter.77,79 The use 
of PIs in combination therapy has been suspected to contribute 
to increased rates of premature births and malformations.118 
However, this is unlikely owing to the minimal placental 
transfer of PIs,119 and any link has not been confirmed by 
other studies.120,121 Increases in the incidence of premature 
births were reported by Thorne and colleagues122 whereas 
no increases were reported by Mandelbrot and colleagues18 HIV/AIDS - Research and Palliative Care 2009:1 46
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or Tuomala and colleagues.120,121 In addition, in a study of 
233 pregnancies, multiple regression analysis revealed no 
association between prematurity rate and the individual PIs 
used or the week of gestation that these drugs were initiated.123 
Nevertheless, owing to possible maternal diabetogenic effects 
and hepatic toxicity, the use of PIs in pregnancy should be 
monitored carefully, especially in the later stages.5,124
There are two characteristics of PIs that are particularly 
relevant to their efficacy and tolerability in pregnancy. First, 
large patient variability in plasma concentrations is a com-
mon feature of PIs and second, considerable data indicate that 
there is a significant association between PI concentration and 
the virologic response and/or toxicity. Thus, the physiologic 
changes that occur in pregnancy may lower PI plasma levels 
below the therapeutic minimum.125,126 In one clinical study of 
lopinavir (LPV),127 exposure in pregnant women resulted in 
LPV concentrations of about half that measured in nonpreg-
nant adults receiving standard dosing. Further, only 18% of 
the women studied during the third trimester of pregnancy had 
LPV area under the curve (AUC) above the 10th percentile for 
nonpregnant adults and none exceeded the 50th percentile.126 
All but one of the women were fully suppressed at delivery, 
however, suggesting that the plasma levels of LPV may be 
superior to anticipated efficacy.127 Since approximately 99% 
of LPV is bound to serum proteins,128 pregnancy-related 
decreases in this fraction could yield better viral suppression 
than would be anticipated from total plasma measurements.
Similar results for plasma pharmacokinetics have been 
reported for NFV .129 For example, during the third trimester 
of pregnancy, the mean difference in plasma levels, AUC, 
and trough concentration in NFV-treated participants was 
significantly (P  0.01) lower in pregnant compared with 
nonpregnant women.129 In contrast, pharmacokinetic stud-
ies of SQV in HIV-infected pregnant women reported SQV 
exposures in excess of the AUC, and AUC did not change 
significantly during gestation, labor, and delivery.130 Similar 
findings were reported from a recent study using the new 
Invirase® formulation of SQV (Roche Pharmaceuticals, 
Nutley, NJ).131 Together these findings suggest that SQV is 
a strong PI candidate when considering treatment options 
for pregnant HIV-1-infected patients.
Finally, there have been several case reports, all involving 
pregnant HIV patients showing multi-drug resistance, of the 
incorporation of other protease inhibitors in ARV regimens 
to prevent MTCT. Three of these involved ritonavir-
boosted darunavir;132–134 the other included ritonavir-boosted 
tipranavir.135 All births were by cesarean delivery; in none 
of the cases was there transmission of HIV to the newborn. 
Because of their potency and limited transplacental passage 
protease inhibitors are ideal to be used as strategies for the 
prevention of MTCT. Providers need to be aware of the 
different pharmacokinetic issues with the diverse drugs 
and should choose those with proven efficacy and adequate 
maternal drug levels.
Fusion/entry inhibitors
The US Food and Drug Administration has designed a drug 
toxicity classification system.136 This system classifies drugs 
from A to D based on the potential risks to a fetus during 
pregnancy. Both enfuvirtide (ENF) and MVC are in cat-
egory B (ie, drugs that, in animal reproduction studies, fail 
to demonstrate a risk to the fetus; however, well-controlled 
studies of pregnant woman have not been conducted).5 What 
is the likelihood that these drugs will cross the placenta? The 
molecular weight of ENF is 4492 Da and therefore is too 
large a molecule to diffuse across the placenta. Still, MVC, 
with a molecular weight of 514 Da, is likely to exhibit lim-
ited transplacental diffusion. Since MVC is a substrate for 
the efflux transporter P-gp, this limited diffusion should be 
reduced further to the extent that placental transfer would be 
minimal.52 The chemokine coreceptor 5 inhibitor still under 
development, vicriviroc, has a molecular weight of 557 Da, 
similar to that of MVC but it has been reported in at least in 
vitro studies not to be a substrate for P-gp. Thus, vicriviroc 
should exhibit limited transplacental diffusion.137–139
Integrase inhibitors
Raltegravir (RAL) is the first integrase inhibitor to receive 
FDA approval. Raltegravir limits the preparatory step that 
inserts the viral DNA into the exposed regions of the DNA of 
the host cell. With a molecular weight of 483 Da (Table 1), 
RAL is likely to partially pass through the placenta, assuming 
a low affinity for the P-gp transporter.51 In preliminary animal 
studies, the drug was found to readily cross the placenta in 
rats and to a limited extent in rabbits,5 and it is classified as 
FDA pregnancy category C (ie, drugs for which safety in 
human pregnancy has not been determined; animal studies 
are either positive for fetal risk or have not been conducted). 
Similarly, the integrase inhibitor elvitegravir, currently under 
development, has a molecular weight of 448 Da and like RAL 
should partially pass through the placental, assuming a low 
affinity for the P-gp transporter.140,141
Nonpharmacologic strategies
A major nonpharmacologic strategy to reduce the MTCT 
of HIV is elective cesarean delivery before the onset of HIV/AIDS - Research and Palliative Care 2009:1 47
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labor.142,143 The effectiveness of elective cesarean delivery 
probably resides in decreasing the exposure of the fetal 
circulation to maternal circulation that normally occurs 
during labor by disruption of the placental barrier. It also 
avoids direct neonate contact with potentially infected 
maternal secretions during passage through the birth canal. 
This is true even if the patient was or was not receiving AZT 
therapy.142–145
Whether scheduled cesarean delivery offers any benefit 
to women with low or undetectable viral loads is not clear. 
For women with HIV RNA  1000 copies/mL, the data are 
insufficient to determine if MTCT rates would be further 
reduced by elective cesarean delivery. One retrospective 
chart review study of 2539 women receiving HAART 
found a MTCT rate of 1.3%. Women with HIV RNA levels 
of 1000 copies/mL were reported to have MTCT rates of 
0.8% with scheduled cesarean delivery and 0.5% with all 
other delivery modes.146 In another report from the European 
Collaborative Study of 4525 women receiving HAART,147 
the overall MTCT rate was 2.9%. In this study of a subset of 
560 women with undetectable HIV RNA levels, scheduled 
cesarean delivery was associated with a significant reduction 
in MTCT in univariate analyses (P = 0.0004).147 However, 
after adjustment for ARV therapy (none versus any), the 
effect was no longer significant (P = 0.36). Very similar 
results, suggesting the possibility of vaginal delivery in 
cases of adequate viral suppression, were reported in the 
study of the French Perinatal Cohort, where elected cesarean 
section was associated with a lower MCTC risk in the overall 
population but not among women delivering with viral loads 
less than 400 copies/mL. Among the 2856 women with 
viral loads 400 copies/mL, the MTCT rate was 0.6%, and 
among the 1338 mothers with viral loads 50 copies/mL, 
the rate was only 0.4%.148 It should be noted, moreover, that 
cesarean deliveries carry an additional risk of postpartum 
morbidity. In a retrospective study of 401 HIV-infected 
women, the incidence of serious postpartum complications 
was 12% after emergency cesarean deliveries, 6.4% 
after elective cesarean deliveries, and 4% after vaginal 
deliveries.149 A cohort study of 299 vaginal deliveries, 
260 elective cesarean deliveries and 139 cesareans with 
ruptured membranes in Latin America and the Caribbean 
showed low morbidity associated to elective cesareans with 
an unadjusted OR of 1.16 (95% CI: 0.5, 2.7). Morbidity was 
higher (odds ratio (OR), 2.96; 95% CI: 1.3, 6.7) for those 
with ruptured membranes or procedures after labor.150 Taken 
together, the data from these various reports are not sufficient 
to confirm or to rule out a benefit from scheduled cesarean 
delivery among women with HIV RNA  1000 copies/mL 
who are receiving HAART.147
The American College of Obstetricians and Gynecologists 
(ACOG) Committee on Obstetric Practice and the 
Perinatal HIV Guidelines Working Group have issued 
guidelines for the best route of delivery for pregnant 
women with HIV infection.151 For women with HIV 
RNA levels 1000 copies/mL and who are receiving ARVs, 
both panels recommend consideration of scheduled cesarean 
delivery for women near to the time of delivery.151 For women 
with HIV RNA levels 1000 copies/mL, the decisions on 
the mode of delivery should be individualized. German-
Austrian recommendations for HIV therapy in pregnancy 
closely reflect those of the ACOG and the Perinatal HIV 
Guidelines Working Group.152 There may be other maternal 
reasons for the choice of an elective cesarean delivery. The 
ACOG recommends that patient’s autonomy regarding their 
decision regarding route of delivery must be respected, and 
ultimately the decision must be individualized according to 
circumstances.151
If the decision is made to perform a scheduled cesarean 
delivery to prevent MTCT, ACOG recommends that it be 
done at 38 weeks’ gestation as determined by the best clinical 
and sonographic estimates and to avoid amniocentesis.151 
Unfortunately, in many resource-constrained settings, 
elective cesarean delivery is seldom feasible.153 Therefore, in 
these settings, the efforts to prevent HIV infection in infants 
are limited to reducing MTCT around the time of labor and 
delivery, which generally accounts for one-third to two-thirds 
of overall transmission (depending on whether the mother 
then breastfeeds).1
The other nonpharmacologic method that can reduce 
the MTCT of HIV is avoidance of breastfeeding. Breast 
milk, which can carry HIV , can increase the likelihood of 
MTCT.25 The highest concentration of HIV per mL of breast 
milk is found in colostrum, or early milk.154 It is not clear 
to what extent breastfeeding influences the efficacy of ARV 
therapy since only a few trials in breastfeeding populations 
(all conducted in Africa) report HIV transmission rates 
beyond 4 to 8 weeks and the results differ by study.9,155–159 
In the HIVNET 012 trial,157 the initial reduction in perinatal 
transmission was maintained at 18 months in a breastfeeding 
population, a finding supported by those in the DITRAME 
(Diminution de la Transmission Mere–Enfant) trial.156–160 
In contrast, the PETRA (Perinatal Transmission) study159 
examined the efficacy of short-course treatment regimens 
with AZT and 3TC in a predominantly breastfeeding 
population and reported that early reductions in HIV infection HIV/AIDS - Research and Palliative Care 2009:1 48
Zorrilla and Tamayo-Agrait Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
rates and HIV infection or mortality at 4 to 8 weeks declined 
and became statistically nonsignificant by 18 months. 
A prospective study following 236 infants from birth until 
24 months of age born to HIV-positive mothers in Harare, 
Zimbabwe,161 reported that breastfed infants had the greatest 
cumulative relative risk of MTCT of HIV-1, followed by 
mixed-fed infants, with the highest incidences occurring 
within the first 3 months. The guidelines established by the 
Perinatal HIV Guidelines Working Group and the WHO do 
not recommend breastfeeding for HIV-infected women where 
safe, affordable, and feasible alternatives are available and 
culturally acceptable.5,162
Where avoidance of breastfeeding is not feasible, 
however, multiple studies have evaluated the role of ARV 
prophylaxis in preventing HIV transmission. In the MASHI 
Study, breastfeeding with a concurrent six months of AZT 
infant prophylaxis was not as effective as formula feeding 
with a concurrent one month of AZT infant prophylaxis in 
preventing HIV transmission to the infants at seven months 
(9.0% vs 5.6%, respectively); however the formula-feeding 
regimen had a higher cumulative mortality rate than the 
breastfeeding regimen (9.3% vs. 4.9%), resulting in com-
parable HIV-free survival rates at 18 months.163 In the Mitra 
Study, in which breastfed infants received daily 3TC for up to 
six months, the cumulative infection rate, 3.8% at six weeks, 
increased only to 4.9% at six months.164 Other studies have 
examined the efficacy of giving HAART to mothers during 
breastfeeding. In the single-arm Kisumu Breastfeeding Study 
in which maternal HAART was continued until weaning at 
six months and infants received a single dose of NVP at birth, 
the infant HIV infection rate at 12 months was 5.9%.165 In the 
Drug Resource Enhancement against AIDS and Malnutrition 
(DREAM) program, MTCT rates at six months were 0.8% 
among breastfed infants of women receiving HAART and 
1.8% among formula-fed infants (P = 0.38).166 The AMATA 
Study compared formula feeding to breastfeeding in women 
who all received NNRTI-based triple therapy; 1.4% of chil-
dren were already infected at birth there but there were no 
additional children infected through breastfeeding.167 While 
further work is required, to better define these MTCT rates, 
these data support the continued administration of HAART 
to women in contexts where suspension of breastfeeding is 
impractical.
Mother and child perinatal/
postnatal HIV care: the future
As women comprise a growing proportion of the HIV-infected 
population, it is important to consider gender-specific, 
perinatal, and postnatal issues when assessing treatment 
options. Different ARV pharmacokinetic profiles in women 
(relative to men) and in pregnant versus nonpregnant women 
merit more research to define therapeutic ranges in drug 
metabolism before and during pregnancy. The maternal 
and fetal efficacy and toxicity of ARVs remain important 
concerns for women of childbearing potential and warrant 
future studies to ensure the safety and long-term well-being 
of both mother and fetus.
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